NOT-AI-20-065 Notice of Special Interest (NOSI): Availability of Emergency Awards for limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2

Applications will be accepted once a month from September 14, 2020 through September 14, 2021

Funder: NIH: National Institute of Allergy and Infectious Diseases (NIAID)

This Notice of Special Interest encourages cooperative agreement applications for implementation of investigator-initiated high-risk clinical trials, as defined by NIAID in PAR-18-633 and NOT-AI-16-084, that will augment ongoing and planned clinical trials of therapeutic and vaccine candidates directed against SARS-CoV-2 to evaluate:

  •  SARS-CoV-2 candidate vaccines
  • non-vaccine biomedical prevention of SARS-CoV-2 infection and/or COVID-19
  • therapeutic approaches to treat COVID-19

Learn More Contact OSR to Apply

Topics: Health Disparities, Research Tool Development, Treatments, Antibody-based Treatment, Convalescent Serum, Drug Development, Drug Repurposing, Drug Targets, Drugs, Immunological Response Targets, Vaccine Efficacy, Vaccine Reliability, Vaccine Scalability, Vaccines